NCT01677962

A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma

A Feasibility and Safety Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Medical University of South Carolina · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to examine the safety of the study drug in patients with locally advanced unresectable pancreatic adenocarcinoma. The study team would like to know about any side effects a patient may have when given the study drug. Another goal of the study is to determine if combining dendritic cells and the study drug can be possibly used as a vaccine for this disease. Dendritic cells are cells that are present in the body's immune system that help your body fight disease.

Conditions

• Pancreatic Adenocarcinoma Non-resectable

Interventions

Type	Name	Description
BIOLOGICAL	Poly-ICLC
BIOLOGICAL	dendritic cell

Timeline

• Start date: 2012-08-01
• Primary completion: 2014-09-01
• Completion: 2016-05-01
• First posted: 2012-09-03
• Last updated: 2016-12-15

Locations

1 site across 1 country: United States